Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

81. Can Multidetector Computed Tomography Rule Out Left Atrial Thrombus in Patients With Atrial Fibrillation? (SRS Diagnosis)

Can Multidetector Computed Tomography Rule Out Left Atrial Thrombus in Patients With Atrial Fibrillation? (SRS Diagnosis) TAKE-HOME MESSAGE Multidetector computed tomography (CT) is a sensitive test to detect left atrial thrombus in patients with atrial ?brillation. Can Multidetector Computed Tomography Rule Out Left Atrial Thrombus in Patients With Atrial Fibrillation? EBEM Commentators Christopher J. Solie, DO Nicholas M. Mohr, MD, MS Daniel P. Runde, MD Department of Emergency Medicine (...) cardioversion of atrial ?brillation? J Am Coll Cardiol. 1994;23:533-541. 6. Romero J, Husain SA, Kelesidis I, et al. Detection of left atrial appendage thrombus by cardiac computed tomography inpatients with atrial fibrillation: a meta-analysis. Circ Cardiovasc Imaging. 2013;6:185-194. 7. Manning WJ, Weintraub RM, Waksmonski CA, et al. Accuracy of transesophageal echocardiography for identifying left atrial thrombi. A prospective, intraoperative study. Ann Intern Med. 1995;123:817-822. 8. Hwang JJ, Chen JJ

2018 Annals of Emergency Medicine Systematic Review Snapshots

82. Stroke Prevention in Patients With Atrial Fibrillation: A Systematic Review Update

Stroke Prevention in Patients With Atrial Fibrillation: A Systematic Review Update PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE In partnership with Stroke Prevention in Patients With Atrial Fibrillation: A Systematic Review Update October 2018Comparative Effectiveness Review Number 214 Stroke Prevention in Patients With Atrial Fibrillation: A Systematic Review Update Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville (...) at: www.effectivehealthcare.ahrq.gov. Search on the title of the report. Persons using assistive technology may not be able to fully access information in this report. For assistance contact epc@ahrq.hhs.gov. Suggested citation: Sanders GD, Lowenstern A, Borre E, Chatterjee R, Goode A, Sharan L, Allen LaPointe NM, Raitz G, Shah B, Yapa R, Davis JK, Lallinger K, Schmidt R, Kosinski A, Al-Khatib S. Stroke Prevention in Patients With Atrial Fibrillation: A Systematic Review Update. Comparative Effectiveness Review No. 214. (Prepared

2018 Effective Health Care Program (AHRQ)

83. Standardized Library of Atrial Fibrillation Outcome Measures

Standardized Library of Atrial Fibrillation Outcome Measures Research White Paper Standardized Library of Atrial Fibrillation Outcome Measures Research White Paper Standardized Library of Atrial Fibrillation Outcome Measures Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2014-00004-C Prepared by: L&M Policy Research, LLC Washington, DC With partner: OM1, AcademyHealth (...) access information in this report. For assistance contact epc@ahrq.hhs.gov. Suggested citation: Gliklich RE, Leavy MB, Li F. Standardized Library of Atrial Fibrillation Outcome Measures. Research White Paper. (Prepared by L&M Policy Research, LLC under Contract No. 290-2014-00004-C.) AHRQ Publication No. 18(19)-EHC026-EF. Rockville, MD: Agency for Healthcare Research and Quality; November 2018. Posted final reports are located on the Effective Health Care Program search page. DOI: https://doi.org

2018 Effective Health Care Program (AHRQ)

84. Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation

Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation 2018 CCS Focused Update of the Guidelines for the Management of Atrial Fibrillation Consulting Fees/ Honoraria Clinical Trials Other Financial Benefit Laurent Macle Abbott Canada, Bayer, BMS Pfizer, Boehringer Ingelheim, Johnson & Johnson, Servier Johnson & Johnson, Servier Atul Verma Bayer, Johnson & Johnson, Medtronic Johnson & Johnson Jason Andrade Bayer, BMS Pfizer, Medtronic, Servier (...) process. Below is a list of all disclosures for the AF panel, regardless of relevance to the 2018 AF Guideline Update. For more information on the CCS Guideline Development process, please visit www.ccs.ca. Page 1 2018 CCS Focused Update of the Guidelines for the Management of Atrial Fibrillation Consulting Fees/ Honoraria Clinical Trials Other Financial Benefit Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content

2018 Canadian Cardiovascular Society

85. Blood & Clots Series: How do you choose an anticoagulant for stroke prevention in atrial fibrillation? Full Text available with Trip Pro

Blood & Clots Series: How do you choose an anticoagulant for stroke prevention in atrial fibrillation? Blood & Clots Series: How do you choose an anticoagulant for stroke prevention in atrial fibrillation? - CanadiEM Blood & Clots Series: How do you choose an anticoagulant for stroke prevention in atrial fibrillation? In , by Kerstin de Wit October 23, 2018 All the content from the Blood & Clots series can be found . CanMEDS Roles addressed : Expert, health advocate, communicator Case (...) Description A 52 year old lady attends the emergency department with a several week history of palpitations. She is found to have atrial fibrillation. You have started a beta blocker and she is in a stable condition for discharge. You evaluate the need for stroke prevention and discuss the options with her. Main Text A 52 year old lady attends the emergency department with previously unrecognized atrial fibrillation. She has had intermittent palpitations for a month or so and her first ECG showed atrial

2018 CandiEM

86. Chronic atrial fibrillation

Chronic atrial fibrillation Chronic atrial fibrillation - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Chronic atrial fibrillation Last reviewed: February 2019 Last updated: October 2018 Summary Chaotic and irregular atrial arrhythmia, the prevalence of which increases progressively with age. Patients frequently have co-existing cardiac or non-cardiac conditions, such as hypertension, coronary artery disease (...) , pacemakers, and ablation of the atrioventricular node need to be weighed based on multiple clinical factors to optimise patient outcome. Definition Atrial fibrillation (AF) is a supraventricular tachyarrhythmia. It is characterised by uncoordinated atrial activity on the surface ECG, with fibrillatory waves of varying shapes, amplitudes, and timing associated with an irregularly irregular ventricular response when atrioventricular (AV) conduction is intact. [Figure caption and citation for the preceding

2018 BMJ Best Practice

87. Newer technologies for detection of atrial fibrillation. (Abstract)

Newer technologies for detection of atrial fibrillation. Atrial fibrillation is a common arrhythmia that is associated with increased risk of stroke, which can be reduced with appropriate anticoagulation treatment. However, it remains underdiagnosed in contemporary clinical practice using conventional detection methods, resulting in missed opportunities to implement appropriate treatment. Newer technologies developed in recent years can potentially enhance the detection of atrial fibrillation (...) and overcome certain limitations of the conventional methods. However, uncertainties remain about their use and the significance of atrial fibrillation detected by some of these newer technologies. This review examines the evidence supporting the use of some of these technologies and evaluates their applications in certain clinical scenarios.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights

2018 BMJ

88. Using the MB-LATER score for predicting arrhythmia outcome after catheter ablation for atrial fibrillation: The Guangzhou atrial fibrillation project (Abstract)

Using the MB-LATER score for predicting arrhythmia outcome after catheter ablation for atrial fibrillation: The Guangzhou atrial fibrillation project Several clinical scoring systems have been derived to predict the arrhythmia outcome of catheter ablation (CA) for atrial fibrillation (AF) but which is better is not clear. Simple clinical risk scores (that any clinician can use in the everyday clinic) can help assess the likelihood of recurrence of AF following CA and the simple MB-LATER score

2018 EvidenceUpdates

89. A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS Full Text available with Trip Pro

A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS We tested the hypothesis that atrioventricular (AV) junction ablation in conjunction biventricular pacing [cardiac resynchronization (CRT)] pacing is superior to pharmacological rate-control therapy in reducing heart failure (HF) and hospitalization in patients with permanent atrial fibrillation (AF) and narrow QRS.We randomly

2018 EvidenceUpdates

90. Effect of Variation in Published Stroke Rates on the Net Clinical Benefit of Anticoagulation for Atrial Fibrillation. (Abstract)

Effect of Variation in Published Stroke Rates on the Net Clinical Benefit of Anticoagulation for Atrial Fibrillation. Stroke rates in patients with nonvalvular atrial fibrillation (AF) who are not receiving anticoagulant therapy vary widely across published studies; the resulting effect on the net clinical benefit of anticoagulation in AF is unknown.To determine the effect of variation in published AF stroke rates on the net clinical benefit of anticoagulation.Markov model decision analysis (...) and Risk Factors In Atrial Fibrillation) study and greatest using those from the Danish National Patient Registry (6290 QALYs [95% CI, ±2.3%] vs. 24 110 QALYs [CI, ±1.9%]; P < 0.001). The optimal CHA2DS2-VASc score threshold for anticoagulation was 3 or more using stroke rates from ATRIA, 2 or more using those from the Swedish AF cohort study, 1 or more using those from the SPORTIF (Stroke Prevention using ORal Thrombin Inhibitor in atrial Fibrillation) study, and 0 or more using those from the Danish

2018 Annals of Internal Medicine

91. Association of metabolic syndrome with non-thromboembolic adverse cardiac outcomes in patients with atrial fibrillation (Abstract)

Association of metabolic syndrome with non-thromboembolic adverse cardiac outcomes in patients with atrial fibrillation Evidence suggests an excess risk of non-thromboembolic major adverse cardiac events (MACE) associated with atrial fibrillation (AF), particularly in individuals free of overt coronary artery disease (CAD). Metabolic syndrome (MetS) increases cardiovascular risk in the general population, but less is known how it influences outcomes in AF patients. We aimed to assess whether

2018 EvidenceUpdates

92. Screening for Atrial Fibrillation With Electrocardiography: US Preventive Services Task Force Recommendation Statement. Full Text available with Trip Pro

Screening for Atrial Fibrillation With Electrocardiography: US Preventive Services Task Force Recommendation Statement. Atrial fibrillation is the most common type of cardiac arrhythmia (irregular heartbeat), and its prevalence increases with age, affecting about 3% of men and 2% of women aged 65 to 69 years and about 10% of adults 85 years and older. Atrial fibrillation is a major risk factor for ischemic stroke, increasing risk of stroke by as much as 5-fold. Approximately 20% of patients who (...) have a stroke associated with atrial fibrillation are first diagnosed with atrial fibrillation at the time of stroke or shortly thereafter.To issue a new US Preventive Services Task Force (USPSTF) recommendation on screening for atrial fibrillation with electrocardiography (ECG).The USPSTF reviewed the evidence on the benefits and harms of screening for atrial fibrillation with ECG in adults 65 years and older, the effectiveness of screening with ECG for detecting previously undiagnosed atrial

2018 JAMA

93. Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. Full Text available with Trip Pro

Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. We compared clinical outcomes in patients with AF with and without diabetes in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.The main efficacy endpoints were SSE and mortality; safety endpoints were major and major/clinically relevant non-major bleeding. A total of 4547/18 201 (24.9%) patients had diabetes who were

2018 European heart journal. Cardiovascular pharmacotherapy Controlled trial quality: predicted high

94. Atrial fibrillation

Atrial fibrillation Top results for atrial fibrillation - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look (...) like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for atrial fibrillation The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials

2018 Trip Latest and Greatest

95. Should Patients Undergo Atrial Fibrillation Screening for Primary Stroke Prevention?

Should Patients Undergo Atrial Fibrillation Screening for Primary Stroke Prevention? Should Patients Undergo Atrial Fibrillation Screening for Primary Stroke Prevention? – Clinical Correlations Search Should Patients Undergo Atrial Fibrillation Screening for Primary Stroke Prevention? July 26, 2018 7 min read By Dixon Yang, MD Peer Reviewed Abstract Atrial fibrillation (AF) is a common arrhythmia, especially in the elderly, and is often asymptomatic. However, absence of symptoms does not confer (...) be interpreted with caution. While a significant portion of patients with screen-detected AF may qualify for anticoagulation, it is unclear which patients would benefit with improved vascular outcomes. Introduction Atrial fibrillation (AF) is a sustained arrhythmia commonly encountered in clinical practice, especially in those over age 65. [1,2]. However, absence of symptoms does not confer a better prognosis and is [3]. Up to 5% of patients with AF present with ischemic stroke as their first manifestation

2018 Clinical Correlations

96. Usefulness of the Addition of Renal Function to the CHA2DS2-VASc Score as a Predictor of Thromboembolism and Mortality in Patients Without Atrial Fibrillation Full Text available with Trip Pro

Usefulness of the Addition of Renal Function to the CHA2DS2-VASc Score as a Predictor of Thromboembolism and Mortality in Patients Without Atrial Fibrillation Research is conflicting whether kidney function should be incorporated in thromboembolism risk prediction. Our published data showed that the CHA2DS2-VASc score predicts thromboembolism and mortality in those without atrial fibrillation. We used the Rochester Epidemiology Project medical records system to retrospectively evaluate whether (...) adding renal impairment (1 point) to the CHA2DS2-VASc score (-R) enhances the score's prediction of mortality, thromboembolism, and atrial fibrillation in patients without atrial fibrillation. We identified patients that had an implantable cardiac monitoring device placed from January 1, 2004 to December 31, 2013, which was defined as the start date. Follow-up was through March 7, 2016. An implantable device was required to discern the absence of atrial fibrillation. Renal impairment was defined

2018 EvidenceUpdates

97. Source Determination in Atrial Fibrillation Full Text available with Trip Pro

Source Determination in Atrial Fibrillation Techniques to ablate persistent atrial fibrillation (AF) continue to evolve. Recent technological and strategic innovations have included a focus on mapping and ablating AF sources. These attempts have not yet yielded a consistent improvement in clinical outcomes following AF ablation. Advancements in these techniques in the next few years, however, may enhance our ability to map and ablate AF as well as further our understanding of the mechanisms

2018 Arrhythmia & electrophysiology review

98. The Impact of Advances in Atrial Fibrillation Ablation Devices on the Incidence and Prevention of Complications Full Text available with Trip Pro

The Impact of Advances in Atrial Fibrillation Ablation Devices on the Incidence and Prevention of Complications The number of patients with atrial fibrillation currently referred for catheter ablation is increasing. However, the number of trained operators and the capacity of many electrophysiology labs are limited. Accordingly, a steeper learning curve and technical advances for efficient and safe ablation are desirable. During the last decades several catheter-based ablation devices have been

2018 Arrhythmia & electrophysiology review

99. Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation: The mSToPS Randomized Clinical Trial. Full Text available with Trip Pro

Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation: The mSToPS Randomized Clinical Trial. Opportunistic screening for atrial fibrillation (AF) is recommended, and improved methods of early identification could allow for the initiation of appropriate therapies to prevent the adverse health outcomes associated with AF.To determine the effect of a self-applied wearable electrocardiogram (ECG) patch in detecting AF and the clinical

2018 JAMA Controlled trial quality: predicted high

100. Risk of Ischemic Stroke After Perioperative Atrial Fibrillation in Total Knee and Hip Arthroplasty Patients (Abstract)

Risk of Ischemic Stroke After Perioperative Atrial Fibrillation in Total Knee and Hip Arthroplasty Patients To determine if new-onset perioperative atrial fibrillation during arthroplasty represents a benign response to intraoperative cardiac stress or is a risk factor for stroke, we evaluated the subsequent risk of ischemic stroke in patients with new-onset atrial fibrillation occurring during primary total knee arthroplasty (TKA) and total hip arthroplasty (THA).Discharge data of all adult (...) patients undergoing primary TKA or THA from 1997 to 2013 were queried via the New York Statewide Planning and Research Cooperative System database to find patients with new-onset perioperative atrial fibrillation. These patients were then followed up over time to determine their risk of ischemic stroke.Of the 312,636 TKA and 215,610 THA unique patient admissions, 3646 (0.7%) had a diagnosis of new-onset perioperative atrial fibrillation. The cohort of patients with this finding was 58.9% female

2018 EvidenceUpdates